Security
Atossa Therapeutics, Inc. Warrant Exp 05/30/2022 · ATOWW
ATOWWOTCWarrantHistorical · closed May 27, 2022CIK 1488039Updated Oct 12, 2026
Name history
ATOSSA GENETICS INC · through Nov 13, 2019
Current security for this SEC filerATOS · NASDAQ
ATOWW price & chart
Historical security
This listing closed May 27, 2022. Live provider charts are shown only for current listings.
Current security: ATOS
About the company
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need. The Company's lead product candidate, (Z)-endoxifen, is in development across several clinical settings, including potential applications in oncology and rare diseases. Atossa has received FDA Orphan Drug Designation for (Z)-endoxifen for Duchenne muscular dystrophy and Rare Pediatric Disease designations for Duchenne muscular dystrophy and McCune-Albright syndrome. (Z)-endoxifen is not approved for any indication. More information is available at atossatherapeutics.com.
In the news
No coverage from other publishers is available.
SEC disclosures
Recent filings
Entry into a Material Definitive Agreement · Material Modification to Rights of Security Holders · Other Events
Items 1.01, 3.03, 8.01, 9.01
Other Events
Items 8.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 47,608,000Source | 76,444,000Source | 96,252,000Source | 123,532,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 41,299,000Source | 71,084,000Source | 88,460,000Source | 110,890,000Source |
| Assets, CurrentUSD | 45,618,000Source | 74,457,000Source | 92,219,000Source | 118,197,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,128,000Source | 1,165,000Source | 2,162,000Source | — |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | 0Source |
| Other Assets, NoncurrentUSD | 1,990,000Source | 1,987,000Source | 2,323,000Source | 635,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 8,255,000Source | 4,967,000Source | 5,236,000Source | 5,568,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 1,550,000Source | 23,488,000Source | 22,792,000Source | 22,792,000Source |
| Additional Paid in CapitalUSD | 285,840,000Source | 261,256,000Source | 255,987,000Source | — |
| Retained Earnings (Accumulated Deficit)USD | -246,562,000Source | -211,792,000Source | -186,288,000Source | -156,194,000Source |
| Stockholders' Equity Attributable to ParentUSD | 39,353,000Source | 71,477,000Source | 91,016,000Source | 117,964,000Source |
| Additional Paid in Capital, Common StockUSD | — | — | — | 250,784,000Source |
| Liabilities and EquityUSD | 47,608,000Source | 76,444,000Source | 96,252,000Source | 123,532,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 8,255,000Source | 4,967,000Source | 5,236,000Source | 5,568,000Source |
| Accounts Payable, CurrentUSD | 4,293,000Source | 679,000Source | 806,000Source | 2,965,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 1,307,000Source | 919,000Source | 973,000Source | 1,059,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | 8,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 2,646,000Source | 2,292,000Source | 4,621,000Source | — |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 3,614,000Source | -127,000Source | -2,159,000Source | 1,248,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -29,762,000Source | -21,030,000Source | -20,941,000Source | -20,760,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -23,000Source | -19,000Source | -14,000Source | -4,727,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 23,000Source | 19,000Source | 14,000Source | 27,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | 0Source |
| Payments for Repurchase of Common StockUSD | — | 0Source | 1,475,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 0Source | 3,673,000Source | -1,475,000Source | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -29,785,000Source | -17,376,000Source | -22,430,000Source | -25,487,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 2,646,000Source | 2,292,000Source | 4,621,000Source | 6,788,000Source |
| DepreciationUSD | 16,000Source | 17,000Source | 23,000Source | — |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on DisposalUSD | 0Source | -7,000Source | 0Source | -3,000Source |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual AmountUSD | 0Source | 1,710,000Source | 2,990,000Source | — |
| General and Administrative ExpenseUSD | 15,956,000Source | 13,504,000Source | 14,043,000Source | 12,608,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | 2,377,000Source | 4,050,000Source | 4,343,000Source | 877,000Source |
| Net Income (Loss) Attributable to ParentUSD | -34,770,000Source | -25,504,000Source | -30,094,000Source | -26,960,000Source |
| Operating ExpensesUSD | 37,141,000Source | 27,621,000Source | 31,377,000Source | 27,691,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 15,000Source |
| Other Nonoperating Income (Expense)USD | -6,000Source | -223,000Source | -70,000Source | -146,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | 0Source |
| Stock or Unit Option Plan ExpenseUSD | — | — | — | 6,788,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -37,141,000Source | -27,621,000Source | -31,377,000Source | -27,691,000Source |
| Other Nonoperating Income (Expense)USD | -6,000Source | -223,000Source | -70,000Source | -146,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -34,770,000Source | -25,504,000Source | -30,094,000Source | -26,960,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -34,770,000Source | -25,504,000Source | -30,094,000Source | -26,960,000Source |
| Earnings Per Share, BasicUSD per share | -4.04Source | -0.2Source | -0.24Source | -0.21Source |
| Earnings Per Share, DilutedUSD per share | -4.04Source | -0.2Source | -0.24Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 8,611,321Source | 125,859,276Source | 126,081,602Source | 126,624,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 8,611,321Source | 125,859,276Source | 126,081,602Source | — |
| Additional Financial Items | ||||
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual AmountUSD | 0Source | 1,710,000Source | 2,990,000Source | — |
| General and Administrative ExpenseUSD | 15,956,000Source | 13,504,000Source | 14,043,000Source | 12,608,000Source |
| Investment Income, InterestUSD | 2,377,000Source | 4,050,000Source | 4,343,000Source | 877,000Source |
| Operating ExpensesUSD | 37,141,000Source | 27,621,000Source | 31,377,000Source | 27,691,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 15,000Source |
| Research and Development ExpenseUSD | 21,185,000Source | 14,117,000Source | 17,334,000Source | 15,083,000Source |
Filing attachments
atos-ex4_1.htm · 8-K · 2026-10-09
Exhibit 4.1 STAPLED CONTINGENT VALUE RIGHTS AGREEMENT This STAPLED CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of October 8, 2026, is entered into by and between Atossa Therapeutics, Inc., a Delaware corporation (the “Company”), and VStock Transfer, LLC, a California limited liability company, as rights agent (the “Rights Agent”). RECITALS WHEREAS, the Company has received rare pediatric disease designation from the FDA for its product candidate (Z)-endoxifen for the treat…
Read attachment ↗atos-ex99_1.htm · 8-K · 2026-10-09
Exhibit 99.1 Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value Board declares one stapled CVR for each share of Atossa common stock outstanding as of October 19, 2026 record date or issued thereafter CVRs entitle holders to 25% of net proceeds from monetization of Atossa's first qualifying priority review voucher, subject to a $50 million aggregate payment cap SEATTLE, Oct. 9, 2026 /PRNewswire/ -- At…
Read attachment ↗atos-ex99_1.htm · 8-K · 2026-09-29
Exhibit 99.1 Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher Shareholders would receive one CVR for each ATOS share held as of the record date or issued thereafter CVRs would entitle holders to 25% of net proceeds from monetization of Atossa’s first qualifying priority review voucher, subject to a $50 million aggregate payment cap SEATTLE, September 29, 2026 - Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“…
Read attachment ↗atos-ex99_1.htm · 8-K · 2026-09-18
EX-99.1 2 atos-ex99_1.htm EX-99.1 Advancing (Z)-Endoxifen A potential best-in-class oral SERM/SERD for estrogen-driven diseases NASDAQ: ATOS www.atossatherapeutics.com Seattle, Washington Corporate & Investor Presentation September 2026 Exhibit 99.1 Cautionary Note Regarding Forward Looking Statements This presentation contains certain “forward-looking statements” within the meaning of applicable securities laws, including but not limited to, our expectations regarding the Company’s develop…
Read attachment ↗atos-ex99_1.htm · 8-K · 2026-08-07
EX-99.1 2 atos-ex99_1.htm EX-99.1 EX-99.1 Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update SEATTLE, WASHINGTON, August 7, 2026 - Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced its financial results and provided an update on recent corporate developments for the second quarter ended …
Read attachment ↗atos-ex4_1.htm · 8-K · 2026-06-11
EX-4.1 2 atos-ex4_1.htm EX-4.1 EX-4.1 EXHIBIT 4.1 SERIES[A]/[B] COMMON STOCK PURCHASE WARRANT ATOSSA THERAPEUTICS, INC. Warrant Shares: _______ Issue Date: June 12, 2026 Initial Exercise Date: December 12, 2026 THIS SERIES [A]/[B] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or af…
Read attachment ↗